Aurobindo Pharma Ltd. has received approval from the Food and Drug Administration for olopatadine hydrochloride ophthalmic solution 0.1%. Aurobindo said its olopatadine HCl ophthalmic solution product is a generic version of Patanol ophthalmic solution/drops from Alcon, a Novartis company.
The Food and Drug Administration has established the Office of Dietary Supplement Programs (ODSP), raising the program from its previous status as a division under the Office of Nutrition Labeling and Dietary Supplements.
Coty Inc. has named Andraea Dawson-Shepherd as senior vice president of corporate affairs, a newly created position. The beauty care company said late Friday that in the role Dawson-Shepherd will lead Coty’s communication and corporate affairs agenda as it continues its expansion and transformation.
Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. have received approval for Basaglar long-acting insulin (insulin glargine injection, 100 units/ml) in the United States.
Merck has received approval from the Food and Drug Administration for an expanded age indication for Gardasil 9, its 9-valent human papillomavirus (HPV) vaccine.
AstraZeneca plans to acquire the core respiratory business of Takeda Pharmaceutical Co. Ltd. for $575 million. Under the agreement, approximately 200 Takeda staff will transfer to AstraZeneca after the closing of the transaction, expected in the first quarter of 2016.
Peter Greenleaf, chief executive officer of Sucampo Pharmaceuticals Inc., has been appointed as chairman of the board. Sucampo said late Tuesday that Greenleaf, the company’s CEO and a board member since March 2014, is slated to take the reins as chairman on Jan. 1.
General Mills reports that it’s making headway in its effort sodium by 20% across 10 key U.S. retail product categories by the end of this year. The food company said Tuesday that it has met or exceeded its goal in seven of 10 categories, with reductions across the 10 categories ranging from 18%
Sanofi and Boehringer Ingelheim are in talks to swap their animal health and consumer health care businesses, respectively. The companies said Tuesday that the proposed transaction would involve an exchange of Sanofi’s Merial animal health business (“Merial”), valued at €11.4 billion ($12.
The Hershey Co. has hired sales veteran Rob Gehring as global chief sales officer. Hershey said Gehring is slated to assume the post effective Jan. 18. He comes to the company from Coca-Cola North America, where he served as president of the Walmart global team since 2011.
Allergan plc has released Viberzi (eluxadoline), a treatment for irritable bowel syndrome with diarrhea (IBS-D), to U.S. pharmacies. The company said Monday that Viberzi, a twice-daily oral medication, relieves the core symptoms of IBS-D: recurrent diarrhea and abdominal pain.
Endo International plc has received an extension of its exclusive U.S. marketing rights for Voltaren Gel (diclofenac sodium topical gel 1%), a nonsteriodal anti-inflammatory drug (NSAID). Endo said Monday that it also was granted extended U.S.
Newell Rubbermaid Inc. is buying Jarden Corp. for about $13.2 billion in cash and stock, combining brands including Paper Mate, Sunbeam and Yankee Candle. Jarden shareholders will receive, per share, $21 and 0.862 shares of Newell Rubbermaid stock at closing.
Horizon Pharma plc plans to acquire Crealta Holdings LLC for $510 million in cash. Horizon said the deal will bring the company Krystexxa (pegloticase), the first and only Food and Drug Administration-approved drug for chronic refractory gout.
Takeda Pharmaceutical Co. has released Ninlaro capsules (ixazomib), a blood cancer medication, in the United States. Takeda said Friday that Ninlaro is the first and only oral proteasome inhibitor.
Jelly Belly Candy Co. has a way for the Force to be with retailers. For the debut of the major motion picture “Star Wars: The Force Awakens” on Dec. 18, the candy maker next month plans to release two new products for its Star Wars Collection of gifts: the 8.5-oz. “Star Wars: The Force Awakens”
